To explore more related to drug selection in clinical use for cancer patient, we queried CMap database using CLUE and identified potential perturbations that could reverse the over-expression signature of TOP2A, CENPF and their common regulons (supplementary Table 9). This evidence concerns the gene CENPF and cancer.